{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:48:14Z","timestamp":1791665294491,"version":"4.3.4"},"reference-count":46,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2015,12,22]],"date-time":"2015-12-22T00:00:00Z","timestamp":1450742400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"DOI":"10.1371\/journal.pmed.1001924","type":"journal-article","created":{"date-parts":[[2015,12,22]],"date-time":"2015-12-22T18:57:07Z","timestamp":1450810627000},"page":"e1001924","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":97,"title":["Risks and Benefits of Nalmefene in the Treatment of Adult Alcohol Dependence: A Systematic Literature Review and Meta-Analysis of Published and Unpublished Double-Blind Randomized Controlled Trials"],"prefix":"10.1371","volume":"12","author":[{"given":"Cl\u00e9ment","family":"Palpacuer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Laviolle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9my","family":"Boussageon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Michel","family":"Reymann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Bellissant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Naudet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,12,22]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(09)60746-7","article-title":"Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders","volume":"373","author":"J Rehm","year":"2009","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"e1001767","DOI":"10.1371\/journal.pmed.1001767","article-title":"Alcohol harm reduction: corporate capture of a key concept","volume":"11","author":"J McCambridge","year":"2014","journal-title":"PLoS Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0306-4603(02)00294-0","article-title":"Harm reduction approaches to alcohol use: health promotion, prevention, and treatment","volume":"27","author":"GA Marlatt","year":"2002","journal-title":"Addict Behav"},{"key":"ref4","unstructured":"European Medicines Agency. Assessment report: Selincro\u2014international non-proprietory name: nalmefene. EMA\/78844\/2013. 13 Dec 2012. Available: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002583\/WC500140326.pdf<\/ext-link>. Accessed 16 November 2015."},{"key":"ref5","year":"2014"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s40273-015-0272-0","article-title":"Nalmefene for reducing alcohol consumption in people with alcohol dependence: an evidence review group perspective of a NICE single technology appraisal","volume":"33","author":"M Stevenson","year":"2015","journal-title":"Pharmacoeconomics"},{"key":"ref7","year":"2013"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"g7544","DOI":"10.1136\/bmj.g7544","article-title":"German evaluation says new drug for alcohol dependence is no better than old one","volume":"349","author":"N Stafford","year":"2014","journal-title":"BMJ"},{"key":"ref9","unstructured":"Tandv\u00e5rds-och L\u00e4kemedelsf\u00f6rm\u00e5nsverket. Selincro ing\u00e5r inte i h\u00f6gkostnadsskyddet. 3 Mar 2015. Available: http:\/\/www.tlv.se\/beslut\/beslut-lakemedel\/avslag-uteslutningar\/Selincro-ingar-inte-i-hogkostnadsskyddet<\/ext-link>. Accessed 16 November 2015."},{"key":"ref10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2147\/SAR.S45666","article-title":"Nalmefene: a new approach to the treatment of alcohol dependence","volume":"5","author":"F Paille","year":"2014","journal-title":"Subst Abuse Rehabil"},{"key":"ref11","first-page":"1347","article-title":"Patient preferences and perspectives regarding reducing alcohol consumption: role of nalmefene","volume":"8","author":"A Luquiens","year":"2014","journal-title":"Patient Prefer Adherence"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"g1531","DOI":"10.1136\/bmj.g1531","article-title":"Bad medicine: nalmefene in alcohol misuse","volume":"348","author":"D Spence","year":"2014","journal-title":"BMJ"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"g2017","DOI":"10.1136\/bmj.g2017","article-title":"Nalmefene in alcohol misuse: junk evaluation by the European Medicines Agency","volume":"348","author":"A Braillon","year":"2014","journal-title":"BMJ"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/jama.2014.3628","article-title":"Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis","volume":"311","author":"DE Jonas","year":"2014","journal-title":"JAMA"},{"key":"ref15","author":"JPT Higgins"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"JA Sterne","year":"2011","journal-title":"BMJ"},{"key":"ref17","year":"2009"},{"key":"ref18","unstructured":"Schwarzer G. meta: general package for meta-analysis, version 3.6\u20130. 27 May 2014. Available: https:\/\/cran.r-project.org\/src\/contrib\/Archive\/meta\/<\/ext-link>. Accessed 18 November 2015."},{"key":"ref19","unstructured":"Lumley T. rmeta: meta-analysis, version 2.16. 29 October 2012. Available: https:\/\/cran.r-project.org\/web\/packages\/rmeta\/index.html<\/ext-link>. Accessed 18 November 2015."},{"key":"ref20","doi-asserted-by":"crossref","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"A Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"ref21","unstructured":"Guang Y, Pixu S, Minge X. gmeta: a unified meta-analysis approach based on confidence distribution. R package version 2.2\u20133. 2013."},{"key":"ref22","author":"DG Chen","year":"2013"},{"key":"ref23","unstructured":"R\u00fccker G, Schwarzer G, Krahn U, K\u00f6nig J. netmeta: network meta-analysis using frequentist methods, version 0.8\u20130. 26 June 2015. Available: https:\/\/cran.r-project.org\/web\/packages\/netmeta\/index.html<\/ext-link>. Accessed 18 November 2015."},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.euroneuro.2013.02.006","article-title":"A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence","volume":"23","author":"A Gual","year":"2013","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.biopsych.2012.10.020","article-title":"Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene","volume":"73","author":"K Mann","year":"2013","journal-title":"Biol Psychiatry"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1530-0277.2007.00401.x","article-title":"Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study","volume":"31","author":"S Karhuvaara","year":"2007","journal-title":"Alcohol Clin Exp Res"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1177\/0269881114527362","article-title":"Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: a 1-year, randomised controlled study","volume":"28","author":"W van den Brink","year":"2014","journal-title":"J Psychopharmacol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/j.1530-0277.1994.tb00098.x","article-title":"A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence","volume":"18","author":"BJ Mason","year":"1994","journal-title":"Alcohol Clin Exp Res"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archpsyc.56.8.719","article-title":"A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence","volume":"56","author":"BJ Mason","year":"1999","journal-title":"Arch Gen Psychiatry"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/01.jcp.0000130555.63254.73","article-title":"A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence","volume":"24","author":"RF Anton","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1037\/a0016579","article-title":"Longitudinal association between frequency of substance use and quality of life among adolescents receiving a brief outpatient intervention","volume":"23","author":"SJ Becker","year":"2009","journal-title":"Psychol Addict Behav"},{"key":"ref32","first-page":"CD006747","article-title":"Managed alcohol as a harm reduction intervention for alcohol addiction in populations at high risk for substance abuse","volume":"12","author":"W Muckle","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"e005376","DOI":"10.1136\/bmjopen-2014-005376","article-title":"The cost-effectiveness and public health benefit of nalmefene added to psychosocial support for the reduction of alcohol consumption in alcohol-dependent patients with high\/very high drinking risk levels: a Markov model","volume":"4","author":"P Laramee","year":"2014","journal-title":"BMJ Open"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1177\/0269881115602487","article-title":"Clinical relevance of nalmefene versus placebo in alcohol treatment: reduction in mortality risk","volume":"29","author":"M Roerecke","year":"2015","journal-title":"J Psychopharmacol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/alcalc\/agt061","article-title":"Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies","volume":"48","author":"W van den Brink","year":"2013","journal-title":"Alcohol Alcohol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"e1553","DOI":"10.1136\/bmj.e1553","article-title":"Credibility of claims of subgroup effects in randomised controlled trials: systematic review","volume":"344","author":"X Sun","year":"2012","journal-title":"BMJ"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1111\/j.1530-0277.2011.01524.x","article-title":"Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence","volume":"35","author":"HM Pettinati","year":"2011","journal-title":"Alcohol Clin Exp Res"},{"key":"ref38","unstructured":"National Institute for Health and Care Excellence. Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence. NICE guidelines CG115. London: National Institute for Health and Care Excellence; 2011."},{"key":"ref39","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/CVM-1-1-025","article-title":"Debate: subgroup analyses in clinical trials: fun to look at\u2014but don\u2019t believe them!","volume":"1","author":"P Sleight","year":"2000","journal-title":"Curr Control Trials Cardiovasc Med"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/jama.2013.285063","article-title":"How to use a subgroup analysis: users\u2019 guide to the medical literature","volume":"311","author":"X Sun","year":"2014","journal-title":"JAMA"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.biopsych.2013.03.002","article-title":"Naltrexone and nalmefene: any meaningful difference?","volume":"73","author":"RM Swift","year":"2013","journal-title":"Biol Psychiatry"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/add.12875","article-title":"The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis","volume":"110","author":"K Donoghue","year":"2015","journal-title":"Addiction"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1136\/bmj.332.7547.969","article-title":"Reporting attrition in randomised controlled trials","volume":"332","author":"JC Dumville","year":"2006","journal-title":"BMJ"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.biopsych.2005.10.020","article-title":"Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology","volume":"59","author":"AC Leon","year":"2006","journal-title":"Biol Psychiatry"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1111\/acer.12543","article-title":"Methods to analyze treatment effects in the presence of missing data for a continuous heavy drinking outcome measure when participants drop out from treatment in alcohol clinical trials","volume":"38","author":"K Witkiewitz","year":"2014","journal-title":"Alcohol Clin Exp Res"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0895-4356(94)00098-B","article-title":"Selecting the language of the publications included in a meta-analysis: is there a Tower of Babel bias?","volume":"48","author":"G Gregoire","year":"1995","journal-title":"J Clin Epidemiol"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pmed.1001924","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T11:03:56Z","timestamp":1589022236000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1001924"}},"subtitle":[],"editor":[{"given":"Wayne D.","family":"Hall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,12,22]]},"references-count":46,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2015,12,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1001924","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,22]]}}}